Список проголосовавших за комментарий " Gapping up/down: AVAV +7%, PLCE +7%, HRB +6% and OA +1% after earnings, MIK +2% after upgrade, SWKS +1% after OP initiation at Wells Fargo; VRA -14%, EXPR -12%, URBN -7% and CIEN -4% after earnings<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>MFIN</strong> +35.1%, <strong>HH</strong> +31.7%, <strong>PRSS</strong> +19.2%, <strong>REXX</strong> +17.5%, <strong>BIOC</strong> +17.3%, <strong>EKSO</strong> +11.1%</li><li><strong>AVAV</strong> +7.1%, <strong>YIN</strong> +7.1%, <strong>PLCE</strong> +6.8%, <strong>ZAGG</strong> +6.7%, <strong>SCMP</strong> +6.7%, <strong>CLNE</strong> +6.6%, <strong>HRB</strong> +6%</li><li><strong>TLGT</strong> +3.8%, <strong>NCS</strong> +3.4%, <strong>REGI</strong> +2.8%, <strong>OPTT</strong> +2%, <strong>GTT</strong> +2%, <strong>AERI</strong> +1.8%, <strong>RIGL</strong> +1.5%</li><li><strong>OA</strong> +1.4%, <strong>TISI</strong> +1%, <strong>CERS</strong> +0.8%, <strong>CBIO</strong> +0.7%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>TSL</strong> +5.7% (still checking, potentially related to pending to «go private» soon)</li><li><strong>RH</strong> +1.9% (UK Betaville blogger suggests Williams-Sonoma is 'stalking Restoration Hardware')</li></ul><p><strong>Select EU financial names showing strength</strong>:</p><ul><li><strong>ING</strong> +2%, <strong>CS</strong> +1.8%, <strong>DB</strong> +1.4%, LYG +1%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>PRKR</strong> +50.2% (continued strength following favorable patent ruling)</li><li><strong>XTLB</strong> +14.4% (continued strength)</li><li>S<strong>HIP</strong> +12.6% (enters into a definitive agreement with one of its senior lenders for the early termination of a credit facility, which is expected to result into a material gain and equity accretion; the gain to the Company is estimated to be approximately $11.4 million after completion)</li><li><strong>EXTR</strong> +7.4% ( to acquire Avaya's networking business for approximately $100 million )</li><li><strong>NTLA</strong> +5.1% (presents updated data showing increased levels of genome editing efficiency in vivo and durability results with its CRISPR/Cas9 technology)</li><li><strong>CLRB</strong> +4.5% (enters into a licensing agreement with the Wisconsin Alumni Research Foundation for intellectual property rights covering the method of use for CLR 131), <strong>TLGT</strong> +3.8% (receives approval of the Co's abbreviated new drug application from the FDA of Clobetasol Propionate Gel)</li><li><strong>KERX</strong> +3.3% (FDA has accepted for review the supplemental New Drug Application for Auryxia)</li><li><strong>OPK</strong> +2.8% (receives notification from the EC designating its oligonucleotide-based AntagoNAT)</li><li><strong>FCSC</strong> +1.9% (Fibrocell Science entered into securities purchase agreement with existing investors for sale of $8.0 mln Series A Convertible Preferred Stock and accompanying warrants )</li><li><strong>DKS</strong> +0.9% (slightly rebounding following yesterday's 9% decline, also several analysts defending stock this morning)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>MIK</strong> +2.6% (upgraded to Buy from Neutral at BofA/Merrill)</li><li><strong>IPXL</strong> +2.2% (upgraded to Buy from Hold at Deutsche Bank)</li><li><strong>MWA</strong> +1.6% (initiated with a Buy at Goldman)</li><li><strong>SWKS</strong> +1% (initiated with a Outperform at Wells Fargo)</li><li><strong>AVB</strong> +1% (upgraded to Buy from Neutral at BofA/Merrill)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>GNE</strong> -14.7%, <strong>VRA</strong> -14.2%, <strong>EXPR</strong> -11.9%,</li><li><strong>ALQA</strong> -11.5%, (also initiated a process of identifying strategic alternatives for the contract manufacturing business )</li><li><strong>ARA</strong> -10.9%, <strong>HYGS</strong> -8.9%, <strong>PQ</strong> -8.7%, <strong>URBN</strong> -6.7%, <strong>BOJA</strong> -6.1%, <strong>CIEN</strong> -3.9%, <strong>BOBE</strong> -3.6%</li><li><strong>RGNX</strong> -2.6%, (also announces that the first patient in a Phase I/II clinical trial of REGENXBIO's investigational gene therapy RGX-501 for the treatment of homozygous familial hypercholesterolemia has been dosed)</li><li><strong>KODK</strong> -2.5%, <strong>RRR</strong> -1.4%</li></ul><p><strong>Select metals/mining stocks trading lower</strong>:</p><ul><li><strong>GFI</strong> -3.5%, <strong>SBGL</strong> -3.4%, <strong>AG</strong> -2.6%, <strong>HMY</strong> -2.3%, <strong>BHP</strong> -1.9%, <strong>AUY</strong> -0.8%, <strong>ABX</strong> -0.7%</li></ul><p><strong>Select oil/gas related names showing early weakness</strong>:</p><ul><li><strong>RIG</strong> -1.4%, <strong>RDS.A</strong> -1.2%, <strong>MRO</strong> -1%, <strong>BP</strong> -0.8%, <strong>TOT</strong> -0.8%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>HIIQ</strong> -15% (launches a secondary underwritten public offering of shares of its Class A common stock )</li><li><strong>GEO</strong> -6.3% (prices its previously announced public offering of 6,000,000 shares at $41.75/share)</li><li><strong>LADR</strong> -4.8% (prices 3 mln common stock offering by selling stockholders for gross proceeds of approx. $42 mln)</li><li><strong>FOXF</strong> -4.2% (announces secondary offering of 5,108,718 shares by one of its existing stockholders)</li><li><strong>LAND</strong> -3.9% (to sell approx. 1.4 mln shares of its common stock in an underwritten public offering)</li><li><strong>CAT</strong> -2.1% (NY Times report discussing allegations of tax fraud)</li><li><strong>COTV</strong> -2% (prices offering of 8.42 mln shares of common stock, by certain stockholders at a $36.00 per share)</li><li><strong>NVO</strong> -1.2% (Bloomberg details that Novo Nordisk (NVO) might miss its diabetics treatment targets)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>GOLD</strong> -2.1% (downgraded to Underperform at RBC Capital Mkts)</li><li><strong>BT</strong> -1.4% (downgraded to Neutral from Buy at Goldman)</li></ul>"